Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VORINOSTAT for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 11 adverse event reports in the FDA FAERS database where VORINOSTAT was used for Diffuse large b-cell lymphoma refractory.

Most Reported Side Effects for VORINOSTAT

Side Effect Reports % Deaths Hosp.
Febrile neutropenia 177 14.2% 25 84
Product use in unapproved indication 122 9.8% 16 4
Thrombocytopenia 89 7.1% 16 13
Off label use 88 7.1% 18 28
Anaemia 79 6.3% 15 28
Sepsis 77 6.2% 28 40
Diarrhoea 68 5.5% 10 30
Neutropenia 63 5.1% 5 12
Nausea 61 4.9% 14 29
Fatigue 59 4.7% 13 19
Product use issue 55 4.4% 6 3
Platelet count decreased 51 4.1% 16 35
Vomiting 50 4.0% 10 28
Pneumonia 47 3.8% 19 27
Death 46 3.7% 46 12

Other Indications for VORINOSTAT

Acute myeloid leukaemia (253) Plasma cell myeloma (93) Mycosis fungoides (82) Myelodysplastic syndrome (81) Acute lymphocytic leukaemia (69) Product used for unknown indication (52) Cutaneous t-cell lymphoma (38) Peripheral t-cell lymphoma unspecified (34) Ewing's sarcoma (26) Neoplasm malignant (21)

Other Drugs Used for Diffuse large b-cell lymphoma refractory

RITUXIMAB (667) EPCORITAMAB-BYSP (353) AXICABTAGENE CILOLEUCEL (336) BENDAMUSTINE (283) CYCLOPHOSPHAMIDE (226) POLATUZUMAB VEDOTIN (223) ETOPOSIDE (165) POLATUZUMAB VEDOTIN-PIIQ (158) GEMCITABINE (147) LENALIDOMIDE (143)

Related Pages

VORINOSTAT Full Profile All Diffuse large b-cell lymphoma refractory Drugs VORINOSTAT Demographics VORINOSTAT Timeline